RecruitingPhase 1NCT07448194

A Phase Ia Clinical Trial of HW241045

A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets Following a Single Dose in Healthy Subjects: A Single-center, Randomized, Double-blind, Placebo-controlled Study

Sponsor

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Enrollment

56 participants

Start Date

Nov 24, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers IPF

Summary

This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HW241045 and a drug called Placebo for people with healthy volunteers and ipf. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.